Welcome to the TLDR Biotech newsletter!

Our aim is to be your one-stop source for biotech and pharma updates - all with one daily email.

We’ll likely tweak the exact format and delivery over the next few weeks as we get our feet under us.

So if you have any feedback on what you like (or don’t), we’d love to hear from you!

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

THE GOOD
Approvals & Labels

Sapreta Therapeutics could see earlier FDA decision
Gene therapy, duchenne muscular dystrophy - Read more

THE GOOD
Clinical Trials

Amgen hoping for big entry into obesity space
ADC, obesity - Read more

AstraZeneca blockbuster inches towards earlier line cancer treatment
Small molecule, mantle cell lymphoma - Read more

Moderna plots further progress into solid cancers
Cancer vaccines, mRNA, solid tumors - Read more

THE GOOD
Earnings & Finance

Novo Nordisk winning streak continues on GLP-1
$8.7B sales from diabetes and obesity portfolio - 93.3% of 2024Q1 sales
GLP-1, weight-loss - Read more

Oxford Biomedica aims to go global, recover from 2023 revenue drop
Order intake £131 million ($163 million) in 2023; compared to £85 million ($106 million) in 2022
CDMO, cell & gene therapy - Read more

Blueprint Medicines reports strong Q1
$92.5M AYVAKIT net product revenues 2024Q1
Small molecule, cancer - Read more

THE GOOD
Fundraises

Delphia Therapeutics launches with $67M
Activation lethality, cancer - Read more

Reunion Neuroscience raises $103M
Post-partum depression, small molecule, psychedelics - Read more

BridgeBio’s $200M KRAS spin-out
Small molecule, cancer - Read more

Latus Bio launches with $54M
Gene therapy, CNS - Read more

Novocure raises $400M debt financing, launch anticipation
Small molecule, non-small cell lung cancer - Read more 

Corvus Pharmaceuticals $30.6M stock sale
Small molecule, immune disorders, cancer - Read more

Context Therapeutics $100M private placement
Bispecific antibody, solid tumors, cancer - Read more

Ikerian AG $6.18M Series A
AI, medical imaging, optometry - Read more

Remepy totals $15M in funding ($10M seed + $5M earlier)
Digital therapeutics, hybrid therapeutics - Read more

THE GOOD
Mergers & Acquisition, Business Development

Novartis buys Mariana Oncology
$1B upfront, $750M milestones
Radiopharma, radioligands - Read more

THE GOOD
Opinions

What will obesity trial endpoints look like? - Read more

THE GOOD
Partnerships

Quest Diagnostics makes pact to further digital, AI diagnostic technologies
Pathology, AI, cancer - Read more 

THE GOOD
Research

First-in-human mRNA cancer vaccine trials for glioblastoma
Cancer vaccine, solid tumors, mRNA - Read more

THE GOOD
Strategic Plans

Moderna aims for fall RSV launch
RSV vaccines - Read more

THE BAD
Clinical Trials

Sanofi, Regeneron face FDA data-request delay, Dupixent
Small molecule, COPD - Read more

THE BAD
Earnings & Finances

Pricing & supply constraints colluded to slump Novo’s Q1 Wegovy sales
Obesity, GLP-1 - Read more

Amwell reports Q1 sales drop
Telehealth, telemedicine - Read more

THE BAD
Layoffs

Emergent lays-off 300 employees, shutters two sites
CDMO - Read more

Chroma Medicine layoffs, undisclosed number
Epigenetic editor, platform tech - Read more

THE BAD
Partnerships

Moderna and Metagenomi part ways
Gene editing - Read more

Bristol Myers Squibb hands back drug to Schrödinger
Small molecule, cancer - Read more

THE BAD
Research

ChatGPT has a hard time with cardiac risk assessment - Read more

THE UGLY
Guidelines

Breast cancer screening guidelines revised, as younger people are getting cancer more often - Read more

THE UGLY
Lawsuits

Insight Global agrees to $2.7M settlement for alleged COVID-era cybersecurity snafu
Cybersecurity, contact tracing - Read more

THE UGLY
Policy & Politics

With the IRA here to stay, Big Pharma downplays bottom-line impact
Inflation Reduction Act - Read more

THE UGLY
Regulatory

Drug pricing watchdog calls BS on FDA courting full approval to Sarepta’s DMD gene therapy
Gene therapy, accelerated approvals - Read more

You’re all caught up on the latest Pharma & Biotech News!

We want to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send us an email - we want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️